Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciprofloxacin inhalation - Aradigm

Drug Profile

Ciprofloxacin inhalation - Aradigm

Alternative Names: Apulmiq; ARD-1100; ARD-3100; ARD-3150; CFI; Ciprofloxacin AERx formulation - Aradigm; Ciprofloxacin inhalation modified-release - Aradigm Corporation; Ciprofloxacin inhalation sustained-release - Aradigm; Ciprofloxacin liposomal sustained-release - Aradigm; DRCFI; Dual Release Ciprofloxacin for Inhalation; ILCH; Inhaled liposomal ciprofloxacin hydrochloride; Linhaliq; Lipoquin; Pulmaquin

Latest Information Update: 04 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aradigm Corporation
  • Developer Aradigm Corporation; Oregon State University
  • Class Anti-infectives; Antibacterials; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
  • Mechanism of Action DNA topoisomerase IV inhibitors; Type II bacterial DNA topoisomerase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchiectasis; Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Bronchiectasis
  • Suspended Cystic fibrosis-associated respiratory tract infections
  • No development reported Acinetobacter infections; Anthrax; Nontuberculous mycobacterium infections; Pneumonic plague; Q fever; Tularaemia; Yersinia infections

Most Recent Events

  • 30 Oct 2019 Regulatory submission withdrawn for Bronchiectasis (Non-cystic fibrosis-related) in European Union (Inhalation)
  • 17 May 2019 Efficacy data from the pooled analysis of ORBIT-3 and ORBIT-4 trials presented at the 115th International Conference of the American Thoracic Society (ATS-2019)
  • 28 Feb 2019 No recent reports of development identified for preclinical development in Pneumonic-plague in USA (Inhalation, Liposomal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top